$6.50
0[0.00%]
At close: Apr 17
$6.50
0[0.00%]
PreMarket: 4:00PM EDT
GoodRx Holdings
(NASDAQ:GDRX)GoodRx Holdings Stock (NASDAQ:GDRX), Analyst Ratings, Price Targets, Predictions
GoodRx Holdings Inc has a consensus price target of $12.8, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Keybanc, Wells Fargo, and RBC Capital on April 10, 2024, March 25, 2024, and March 8, 2024. With an average price target of $9 between Keybanc, Wells Fargo, and RBC Capital, there's an implied 38.46% upside for GoodRx Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Keybanc
Wells Fargo
RBC Capital
UBS
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for GoodRx Holdings
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 38.46% | Keybanc | Scott Schoenhaus | → $9 | Upgrade | Sector Weight → Overweight | Get Alert |
| 03/25/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 53.85% | Wells Fargo | Stan Berenshteyn | → $10 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/08/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 23.08% | RBC Capital | Sean Dodge | → $8 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 15.38% | Wells Fargo | Stan Berenshteyn | $6 → $7.5 | Maintains | Equal-Weight | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 23.08% | UBS | Eric Sheridan | $5 → $8 | Maintains | Neutral | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 23.08% | RBC Capital | Sean Dodge | $7 → $8 | Maintains | Sector Perform | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 15.38% | Goldman Sachs | Eric Sheridan | $6.5 → $7.5 | Maintains | Neutral | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 23.08% | Truist Securities | Jailendra Singh | $7.5 → $8 | Maintains | Hold | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 115.38% | TD Cowen | Charles Rhyee | $12 → $14 | Maintains | Outperform | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 53.85% | JP Morgan | Lisa Gill | $7 → $10 | Upgrade | Neutral → Overweight | Get Alert |
| 03/01/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 38.46% | Barclays | Steve Valiquette | $8 → $9 | Maintains | Overweight | Get Alert |
| 02/26/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 23.08% | Leerink Partners | Michael Cherny | → $8 | Initiates | → Outperform | Get Alert |
| 01/16/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 7.69% | RBC Capital | Sean Dodge | $5 → $7 | Maintains | Sector Perform | Get Alert |
| 01/12/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | 15.38% | Truist Securities | Jailendra Singh | $5.5 → $7.5 | Maintains | Hold | Get Alert |
| 01/02/2024 | GDRX | Buy Now | GoodRx Holdings | $6.50 | -30.77% | B of A Securities | Michael Cherny | $8 → $4.5 | Downgrade | Buy → Underperform | Get Alert |
| 11/17/2023 | GDRX | Buy Now | GoodRx Holdings | $6.50 | -7.69% | JP Morgan | Doug Anmuth | $7 → $6 | Maintains | Neutral | Get Alert |
| 11/13/2023 | GDRX | Buy Now | GoodRx Holdings | $6.50 | -7.69% | Goldman Sachs | Eric Sheridan | $7 → $6 | Maintains | Neutral | Get Alert |
| 11/10/2023 | GDRX | Buy Now | GoodRx Holdings | $6.50 | -23.08% | RBC Capital | Sean Dodge | $8 → $5 | Maintains | Sector Perform | Get Alert |
| 11/10/2023 | GDRX | Buy Now | GoodRx Holdings | $6.50 | -7.69% | Goldman Sachs | Eric Sheridan | $7 → $6 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for GoodRx Holdings (GDRX)?
The latest price target for GoodRx Holdings (NASDAQ: GDRX) was reported by Keybanc on April 10, 2024. The analyst firm set a price target for $9.00 expecting GDRX to rise to within 12 months (a possible 38.46% upside). 41 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GoodRx Holdings (GDRX)?
The latest analyst rating for GoodRx Holdings (NASDAQ: GDRX) was provided by Keybanc, and GoodRx Holdings upgraded their overweight rating.
When was the last upgrade for GoodRx Holdings (GDRX)?
The last upgrade for GoodRx Holdings Inc happened on April 10, 2024 when Keybanc raised their price target to $9. Keybanc previously had a sector weight for GoodRx Holdings Inc.
When was the last downgrade for GoodRx Holdings (GDRX)?
The last downgrade for GoodRx Holdings Inc happened on January 2, 2024 when B of A Securities changed their price target from $8 to $4.5 for GoodRx Holdings Inc.
When is the next analyst rating going to be posted or updated for GoodRx Holdings (GDRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GoodRx Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GoodRx Holdings was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating GoodRx Holdings (GDRX) correct?
While ratings are subjective and will change, the latest GoodRx Holdings (GDRX) rating was a upgraded with a price target of $0.00 to $9.00. The current price GoodRx Holdings (GDRX) is trading at is $6.50, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.